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S254 Poster Session IThe median days for pheresis was 1 day (range, 1-3). The median
SC dose collected was 4 x 106 CD34+ cells/ Kg (range, 2.5 – 14.3).
The median CD-34+ peripheral blood count on the 1st day collec-
tion with P was 22.4/uL. In contrast the median peripheral blood
CD-34+ cell count on the day of failed collection was 6.2 /uL. The
average increase using P was 14.9 CD-34+ cells/uL. We collected
$ 2.5 x 106 CD34+ cells/Kg on 4/5 pts with HD, 13/17 pts with
MM and 16/27 pts with NHL. 16 pts (33%) collected\ 2.5 x 106
CD34+ cells/Kg, with median cell dose of 1.4 x 106 CD34+ cells/
Kg (range, 0.4-2.2). The median number of days of pheresis was 2
days (range, 1-4). For these16 pts the median CD-34+ count on
the day of unsuccessful collection was11.2 /uL, compared to 8.3/
uL with use of P and GCSF. The common side effects attributed
to P were diarrhea, fatigue, thrombocytopenia and bone pain; ob-
served in 12%, 8%, 8% and 6% pts, respectively. 43/ 49 pts pro-
ceeded to an autologus SC transplant, 34 pts received $ 2.5 x 106
CD34+ cells/Kg. Thirty two of these pts used the P collection as
the only source of SC. Two pts had their P mobilized SC combined
with a previous suboptimal SC collection. Nine pts received\2.5 x
106 CD34 + cells/Kg; 4 pts received P mobilized SC alone, 5 pts re-
ceived P mobilized SC combined with their previously mobilized
SC. All pts received GCSF from day +6 till WBC engraftment.
The median days of WBC and platelet engraftment were day +11
(range, 9-13 days) and day +16 (range, 11-77 days), respectively.
With a median follow up of 13.7 months, long term engraftment
data is available on 27 pts. The median white cell count, hemoglobin
and platelet count 1 year after transplant was 4.7 x 109/L, 12.2 g/dL
and 109 x109/L, respectively. To date 15 pts have evidence of disease
progression. Two patients have developed MDS/AML post trans-
plant. Failure to increase peripheral CD34 count after P when com-
pared to previous attempts may predict unsuccessful mobilization.
P is well tolerated with minimal side effects, acceptable time to en-
graftment and acceptable peripheral blood counts at 1 yr after the
transplant.134
OUTCOMES FOLLOWING SALVAGE AUTOLOGOUS STEM CELL TRANS-
PLANT (SCT) FOR MULTIPLE MYELOMA
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Background: High-dose therapy and SCT has improved the pro-
gression-free (PFS) and overall survival (OS) of patients with multi-
ple myeloma (MM). However all patients eventually develop disease
recurrence. In the era of effective novel agents (such as bortezomib,
lenalidomide and thalidomide), the optimal salvage strategy is unde-
fined.
Methods: We retrospectively analyzed the outcomes of patients
who underwent salvage melphalan-based SCT for relapsed MM at
Memorial Sloan-Kettering Cancer Center.
Results: Between 1995 and 2011, 60 patients with MM received an
initial SCT and then second autograft for relapsed disease at our cen-
ter. Conditioning regimen consisted of melphalan 100 (N 5 9), 140
(N5 20) or 200mg/m2 (N5 31). Themedian age at 2nd SCTwas 59
years (range 36-75) and 58% (N 5 35) were male. At the time of 1st
and 2nd transplant, 14% (5/36) and 36% (14/39) of patients whowere
assessed with either karyotype or FISH had high risk cytogenetics
(including t (4;14), +1q, p53 loss, or del 13q by karyotype), respec-
tively. Median interval between first and salvage SCT was 32 mos
(range 7.1-88.7). Of evaluable patients, 78% (46/59) had chemother-
apy sensitive disease prior to salvage SCT and 22% were chemore-
sistant. Twenty-eight patients received maintenance following
salvage SCT, most often IMID-based, while 11 went on to receive
an allogeneic SCT, 3/11 patients were received maintenance prior
to allogeneic SCT. Response was assessed at 2-3 mos post-SCT
and 77% of evaluable patients achieved . 5 partial response (PR),
16% had stable disease (SD), and 7% progressed despite salvage
SCT. Following salvage SCT, 23 patients received maintenance
therapy and 11 went on to allogeneic SCT. The median PFS follow-
ing second autograft was 11.2 mos (95% CI: 7.6-14.5); the median
OS was 24 mos (95% CI: 19-42). Although the numbers were small,
high-risk cytogenetics, the interval from first to second SCT, che-
mosensitivity, response and whether patients received maintenancetherapy or allogeneic SCT following salvage autologous SCT did
not significantly impact PFS or OS in this data set.
Conclusions: Salvage SCT is an effective strategy for relapsed MM
following initial autograft and results in responses in the majority of
patients. Although OS and PFS following salvage SCT is similar to
other salvage strategies, novel conditioning regimens and/or effec-
tive maintenance strategies may improve this approach.135
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Both autologous stem cell transplantation (ASCT) and novel
agents have improved outcomes for patients (pts) with multiple my-
eloma (MM). ASCT is often restricted to fitter pts due to concerns of
excessive treatment-related morbidity and mortality. Pre-transplant
risk-stratification based on comorbidity index (CI) has been recog-
nized as an important decision-making tool in pts with lymphoma
andMM. Although Charlson and hematopoietic cell transplantation
CI (HCT-CI) were previously correlated with post-ASCT toxicities
and length of hospital stay in pts with MM, the groups with higher
scores included fewer pts, limiting study interpretation. We evalu-
ated the prognostic significance of HCT-CI on treatment-related
morbidity (as determined by changes in pulmonary function, length
of hospital stay, and 100-day readmission rate), overall (OS), and
progression-free survival (PFS). Our analysis included 85 consecu-
tive pts (median age, 57 yrs; 68% males) with MM who underwent
ASCT at our institution from 01/2009 to 12/2010. 59% of pts
were in first complete or partial remission prior to ASCT. 65% of
pts had received.1 prior therapy. Median time from diagnosis to
ASCT was 13.4 months. Melphalan-based preparative regimen was
used in 61 pts, whereas others received Bu/Cy on a clinical trial.
24.7% had HCT-CI of 0; 37.6% pts had scores of 1-2; 37.6% pts
had scores$3. Incremental HCT-CI groups were associated with
worse performance status (p\0.001), lower absolute and%predicted
pre-transplant FEV1 (98% vs. 90% vs. 86%, p 5 0.01), lower abso-
lute and % predicted pre-transplant DLCO (91% vs. 78% vs. 66%,
p\0.001), lower % predicted post-transplant DLCO (82% vs. 60%
vs. 75%, p\0.001), longer hospital stay (15 vs. 16 vs. 18 days, p 5
0.03), and faster platelet recovery (17 vs. 12 vs. 12 days, p 5 0.007).
With median follow up of 12 months, 12 pts were readmitted within
100-days of discharge, 12 pts died (9 relapses, 1 heart failure, 1 sepsis,
1 subdural hematoma) with 2 deaths within 100-days from ASCT,
and 12 pts progressed. None of the 3 non-relapse deaths occurred
in the lowest HCT-CI group (two inHCT-CI$3). HCT-CI groups
did not differ by pt readmissions, OS, PFS, and% changes in Pulmo-
nary Function Tests pre- and post-ASCT (all p.0.3). With over
a third of our study pts having HCT-CI$3, we detected no associa-
tion between higher HCT-CI scores and major clinical outcomes.
Our data demonstrate the safety of ASCT in pts with MM who
have higher pre-transplant HCT-CI.136
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Background: High dose therapy followed by autologous stem cell
rescue is the standard of care for transplant eligible patients with
plasma cell myeloma. High dose cyclophosphamide (Cy) at 4-
7mg/m2 with granulocyte colony stimulating factor (GCSF) has
been shown to be an effective regimen for stem cell mobilization de-
spite associated haematologic toxicity. Vinorelbine 25mg/m2 in
